Otros idiomas Almirall, S.A.

Acciones

ALM

ES0157097017

Mercado cerrado - BME Otros sitios de cotización 17:35:26 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
8,57 ^EUR	+1,24 %		+4,00 %	+1,72 %

25/04	EN DIRECTO DESDE LOS MERCADOS: Repsol, Almirall, Enagás, Iberdrola, Técnicas Reunidas, Aedas, Iberdrola, STMicro, Meta...
13/03	Almirall firma un acuerdo de licencia con Eloxx Pharmaceuticals para el tratamiento de enfermedades de la piel	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

LE OPINIONI DEGLI ANALISTI DEL GIORNO : Moncler, Boreo, Fugro, STMicroelectronics, Alfen, Iberdrola, Roche, Temenos, Akzo Nobel...	25/04
IN DIRETTA DAI MERCATI: Moncler, ENI, Webuild, Iberdrola, Adyen, SAES Getters, Xiaomi, Iberdrola, STMicro, Meta...	25/04
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	13/03
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	13/03
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...	19/02
Almirall : le titre bondit après un accord avec Novo Nordisk	19/02
Almirall Secures Global Rights for Blocking Monoclonal Antibody Under Deal with Novo Nordisk	19/02
Les prix américains plombent un peu l'ambiance	19/02
En Direct des Marchés : Alstom, Forvia, Veolia, Casino, Apple, Nintendo, Super Micro Computer...	19/02
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology	19/02
Almirall S.A. Enters into an Exclusive License Agreement with Novo Nordisk	19/02
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business	19/02
Almirall, S.A. Provides Earnings Guidance for the Year 2024	19/02
Almirall, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	19/02
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases	21/12
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases	21/12
Almirall : alliance avec le belge etherna dans l'ARN messager	12/12
Almirall Collaborates with etherna on Development of Severe Skin Disease Therapies	12/12
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology	12/12
Almirall and Etherna Enter into A Multi-Target Alliance to Develop mRNA-Based Therapies in Medical Dermatology	12/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Almirall, S.A.

Acciones

ALM

ES0157097017

Otros idiomas

Filtros